Shore Capital reiterated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Thursday morning.

A number of other research firms also recently weighed in on AZN. Morgan Stanley restated an overweight rating and set a GBX 5,600 ($72.95) target price on shares of AstraZeneca plc in a research report on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.09) target price on AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. Barclays PLC restated an overweight rating and set a GBX 6,000 ($78.17) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. J P Morgan Chase & Co restated a neutral rating on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Deutsche Bank AG restated a buy rating and set a GBX 5,700 ($74.26) target price on shares of AstraZeneca plc in a research report on Monday, June 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company’s stock. AstraZeneca plc has an average rating of Hold and an average target price of GBX 5,085.05 ($66.25).

AstraZeneca plc (AZN) opened at 4544.50 on Thursday. The company’s market cap is GBX 57.53 billion. The company’s 50-day moving average price is GBX 5,161.70 and its 200 day moving average price is GBX 4,861.06. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/astrazeneca-plc-azn-stock-rating-reaffirmed-by-shore-capital/1463125.html.

The company also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 68.90 ($0.90) per share. The ex-dividend date is Thursday, August 10th. This represents a dividend yield of 1.35%.

In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($56.93) per share, with a total value of £1,704.30 ($2,220.30).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.